Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland

OBJECTIVE: This study assessed the cost-effectiveness of nivolumab plus ipilimumab versus both sunitinib and pazopanib for the treatment of first-line unresectable advanced renal cell carcinoma (aRCC) from a healthcare system perspective in Switzerland. METHODS: A three-state partitioned survival mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Çakar, Esra, Oniangue-Ndza, César, Schneider, Ralph P., Klijn, Sven L., Vogl, Ursula M., Rothermundt, Christian, May, Jessica R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333149/
https://www.ncbi.nlm.nih.gov/pubmed/36757568
http://dx.doi.org/10.1007/s41669-023-00395-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333149/
https://www.ncbi.nlm.nih.gov/pubmed/36757568
http://dx.doi.org/10.1007/s41669-023-00395-1

Ejemplares similares